Zobrazeno 1 - 10
of 16
pro vyhledávání: '"SeongShick Ryu"'
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 24, Iss 1, Pp 34-49 (2022)
Hepatocellular carcinoma (HCC) is disease with a high mortality rate and limited treatment options. Alterations of fibroblast growth factor receptor 4 (FGFR4) has been regarded as an oncogenic driver for HCC and a promising target for HCC therapeutic
Externí odkaz:
https://doaj.org/article/e355c3f209df48bb95c0874512458e1d
Autor:
Namkyoung Kim, Injae Shin, Younghoon Kim, Eunhye Jeon, Jiwon Lee, Chaeyoung Lee, Yunju Nam, Sumin Lee, Eunhye Ju, Chan Kim, Woolim Son, SeongShick Ryu, Minjoo Ko, Taebo Sim
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
RAS mutants are involved in approximately 30% of all human cancers and have been regarded as undruggable targets owing to relatively smooth protein surface and obscure binding pockets. In our previous study, we have demonstrated that GNF-7, a multi-t
Externí odkaz:
https://doaj.org/article/ab077dce29e646abaf028b086d8ff2d9
Autor:
Namkyoung Kim, Injae Shin, Jiwon Lee, Eunhye Jeon, Younghoon Kim, Seongshick Ryu, Eunhye Ju, Wonjeong Cho, Taebo Sim
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 7, p 3783 (2021)
Melanoma accounts for the majority of skin cancer deaths. About 50% of all melanomas are associated with BRAF mutations. BRAF mutations are classified into three classes with regard to dependency on RAF dimerization and RAS signaling. The most freque
Externí odkaz:
https://doaj.org/article/00825ae3172043629bb73af20bf574a5
Autor:
SeongShick Ryu, Jung-Eun Park, Young Jin Ham, Daniel C. Lim, Nicholas P. Kwiatkowski, Do-Hee Kim, Debabrata Bhunia, Nam Doo Kim, Michael B. Yaffe, Woolim Son, Namkyoung Kim, Tae-Ik Choi, Puspanjali Swain, Cheol-Hee Kim, Jin-Young Lee, Nathanael S. Gray, Kyung S. Lee, Taebo Sim
Publikováno v:
Journal of Medicinal Chemistry. 65:1915-1932
The polo-box domain (PBD) of Plk1 is a promising target for cancer therapeutics. We designed and synthesized novel phosphorylated macrocyclic peptidomimetics targeting PBD based on acyclic phosphopeptide PMQSpTPL. The inhibitory activities of
Autor:
Yunju Nam, Chan Kim, Junghee Han, SeongShick Ryu, Hanna Cho, Chiman Song, Nam Doo Kim, Namkyoung Kim, Taebo Sim
Publikováno v:
Cancers; Volume 15; Issue 1; Pages: 143
c-KIT is a promising therapeutic target against gastrointestinal stromal tumor (GIST). In order to identify novel c-KIT inhibitors capable of overcoming imatinib resistance, we synthesized 31 novel thiazolo[5,4-b]pyridine derivatives and performed SA
Autor:
Yunju, Nam, Chan, Kim, Junghee, Han, SeongShick, Ryu, Hanna, Cho, Chiman, Song, Nam Doo, Kim, Namkyoung, Kim, Taebo, Sim
Publikováno v:
Cancers. 15(1)
c-KIT is a promising therapeutic target against gastrointestinal stromal tumor (GIST). In order to identify novel c-KIT inhibitors capable of overcoming imatinib resistance, we synthesized 31 novel thiazolo[5,4
Autor:
Chiman Song, SeongShick Ryu, Nam Doo Kim, Nam Hoon Kwon, Taebo Sim, Injae Shin, Eunhye Jeon, Ji Won Lee, Youngji Moon, Young Hoon Kim, Hojong Yoon, Sunghoon Kim, Hwan Geun Choi, Hanna Cho
Publikováno v:
Journal of Medicinal Chemistry. 64:11934-11957
Focal adhesion kinase (FAK) is overexpressed in highly invasive and metastatic cancers. To identify novel FAK inhibitors, we designed and synthesized various thieno[3,2-d]pyrimidine derivatives. An intensive structure-activity relationship (SAR) stud
Autor:
SeongShick Ryu, Yunju Nam, Namkyoung Kim, Injae Shin, Eunhye Jeon, Younghoon Kim, Nam Doo Kim, Taebo Sim
Publikováno v:
Journal of medicinal chemistry. 65(8)
Although FGFR inhibitors hold promise in treating various cancers, resistance to the FGFR inhibitors caused by acquired secondary mutations has emerged. To discover novel FGFR inhibitors capable of inhibiting FGFR mutations, including gatekeeper muta
Autor:
Hanna, Cho, Injae, Shin, Hojong, Yoon, Eunhye, Jeon, Jiwon, Lee, Younghoon, Kim, SeongShick, Ryu, Chiman, Song, Nam Hoon, Kwon, Youngji, Moon, Sunghoon, Kim, Nam Doo, Kim, Hwan Geun, Choi, Taebo, Sim
Publikováno v:
Journal of medicinal chemistry. 64(16)
Focal adhesion kinase (FAK) is overexpressed in highly invasive and metastatic cancers. To identify novel FAK inhibitors, we designed and synthesized various thieno[3,2